Clinical trials
Moderate to Severe Plaque Psoriasis clinical trials
Below are recruiting moderate to severe plaque psoriasis clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04772079RecruitingPhase 3
Test drug safety and effectiveness for youth plaque psoriasis
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Ciudad Autonoma de Buenos Aires, Buenos AiresAges 4–18 - NCT06979453RecruitingPhase 3
A study of deucravacitinib for teens with plaque psoriasis
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 12–17 - NCT07474792RecruitingPhase 2
Study of ORKA-002 for moderate-to-severe plaque psoriasis
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
Birmingham, AlabamaAges 18–79 - NCT06842199RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
Hefei, AnhuiAges 18–75 - NCT04537689RecruitingPhase 4
Test ixekizumab and stopping it in plaque psoriasis
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
Outram ParkAges 22–90 - NCT07672561RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This study tests an experimental pill called WD-890 to see if it can help people with moderate to severe plaque psoriasis. The pill is compared to a placebo (a pill with no medicine) to check if it is safe and works well.
Nanjing, JiangsuAges 18–75 - NCT07251998RecruitingPhase 2
A study of ICP-332 for moderate to severe plaque psoriasis
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06912165RecruitingPhase 2
WD-890 for moderate to severe plaque psoriasis
This study tests an investigational drug called WD-890 for people with moderate-to-severe plaque psoriasis that hasn't responded well enough to other treatments. It may help reduce skin patches, scaling, and itching.
Nanjing, JiangsuAges 18–70 - NCT07326813RecruitingPhase 3
Testing D-2570 for moderate to severe plaque psoriasis
This trial tests if a new oral medication called D-2570 can safely and effectively treat moderate to severe plaque psoriasis. It may be an option if your psoriasis covers a large area and has been stable for at least 6 months.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07234591Recruiting
Study of an oral medication for moderate to severe plaque psoriasis
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
ShanghaiAges 18–70 - NCT07130604RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
Beijing, Beijing MunicipalityAges 18–70 - NCT07129382RecruitingPhase 1/Phase 2
Study of CS32582 for moderate to severe plaque psoriasis
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Beijing, Beijing MunicipalityAges 18–70 - NCT07039110Recruiting
Risankizumab for psoriasis: quality of life study
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
Calgary, AlbertaAges 18 years+ - NCT06696417Recruiting
Testing vunakizumab for moderate to severe plaque psoriasis
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
Shenyang, LiaoningAges 18 years+ - NCT06258668Recruiting
Real-world study of Sotyktu for psoriasis in Korea
This study looks at how safe and effective a pill called Sotyktu is for people with moderate-to-severe plaque psoriasis in real-life medical settings in Korea. If you are 19 or older and are about to start Sotyktu for your psoriasis as your doctor prescribes, this study may be an option for you.
SeoulAges 19 years+ - NCT07250802RecruitingPhase 3
Long-term study of zasocitinib for children with plaque psoriasis
This trial tests a daily pill (zasocitinib) for children and teens with moderate to severe plaque psoriasis that hasn't been controlled by other treatments. It aims to see if the pill can safely improve skin symptoms over a long period.
Chula Vista, CaliforniaAges 4–17 - NCT07038720RecruitingPhase 1
Testing an experimental oral tablet for moderate to severe psoriasis
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Hangzhou, ZhejiangAges 18–55 - NCT07337434RecruitingEarly Phase 1
Comparing two pills for moderate to severe psoriasis
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Peshawar, Khyber PukhtunkhwaAges 18–60 - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+ - NCT03392337Recruiting
Narrowband UVB light therapy for moderate to severe plaque psoriasis
This study tests whether narrowband ultraviolet B (UVB) light given three times a week for 12 weeks improves moderate-to-severe plaque psoriasis. It is an “open-label” pilot, meaning everyone gets the UVB treatment and researchers track how your skin responds.
East Windsor, New JerseyAges 18 years+ - NCT05642182RecruitingPhase 1
Study drug trial for mild to moderate plaque psoriasis
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Pompano Beach, FloridaAges 18 years+ - NCT06030076Recruiting
Switching to tildrakizumab for moderate to severe psoriasis
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
Graz, StyriaAges 18 years+ - NCT06477237RecruitingPhase 3
Testing a new psoriasis shot for moderate to severe plaque
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Jiangmen, GuangdongAges 18–75 - NCT07489885RecruitingPhase 2
Study of D-2570 for moderate to severe plaque psoriasis
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
Birmingham, AlabamaAges 18–70
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe plaque psoriasis?
- Yes. Clin2 currently lists 42 recruiting moderate to severe plaque psoriasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe plaque psoriasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe plaque psoriasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.